Board Meeting7 May 2026, 06:51 pm
Mankind Pharma Board Meeting on May 19, 2026
AI Summary
Mankind Pharma Ltd has scheduled a Board of Directors meeting on May 19, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board will also discuss the realignment of security cover for Non-Convertible Debentures (NCDs) following the redemption of ₹1,250 Crores NCDs on April 16, 2026. The trading window remains closed until May 21, 2026.
Key Highlights
- Board to approve FY26 audited financial results on May 19, 2026.
- Realignment of NCD security cover post ₹1,250 Cr redemption to be considered.
- Trading window closed until May 21, 2026, per insider trading regulations.
- NCD ISIN INE634S07025 has an issue size of ₹12,50,00,00,000.
- NCD ISIN INE634S07033 has an issue size of ₹25,00,00,00,000.
Price Impact
More from MANKIND